The short version of peptide fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
=== Morphine === In the 19th century, two major scientific advances were made that had far-reaching effects. Around 1804, German pharmacist Friedrich Sertürner isolated morphine from opium. He described its crystallization, structure, and pharmacological properties in a well-received paper in 1817. Morphine was the first alkaloid to be isolated from any medicinal plant, the beginning of modern scientific drug discovery. The second advance, nearly fifty years later, was the refinement of the hypodermic needle by Alexander Wood and others. Development of a glass syringe with a subcutaneous needle made it possible to easily administer controlled measurable doses of a primary active compound. Morphine was initially hailed as a wonder drug for its ability to ease pain. It could help people sleep, and had other useful side effects, including control of coughing and diarrhea. It was widely prescribed by doctors, and dispensed without restriction by pharmacists. During the American Civil War, opium and laudanum were used extensively to treat soldiers. It was also prescribed frequently for women, for menstrual pain and diseases of a "nervous character". At first it was assumed (wrongly) that this new method of application would not be addictive.
== Medical uses == Moxetumomab pasudotox as monotherapy is indicated for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).
The main application of ZDDPs are as anti-wear additives in lubricants including greases, hydraulic oils, and motor oils. ZDDPs also act as corrosion inhibitors and antioxidants. Concentrations in lubricants range from 600 ppm for modern, energy-conserving low-viscosity oils to 3000 ppm in some racing oils. It has been reported that zinc and phosphorus emissions may damage catalytic converters and standard formulations of lubricating oils for gasoline engines now have reduced amounts of the additive due to the API limiting the concentration of this additive in new API SM and SN oils; however, this affects only 20- and 30-grade "ILSAC" oils. Grades 40 and higher have no regulation regarding the concentration of ZDDP, except for diesel oils meeting the API CJ-4 specification which have had the level of zddp reduced slightly, although most diesel Heavy-Duty Engine oils still have a higher concentration of this additive. Crankcase oils with reduced ZDDP have been cited as causing damage to, or failure of, classic/collector car flat-tappet camshafts and lifters which undergo very high boundary layer pressures and/or shear forces at their contact faces, and in other regions such as main bearings, and piston rings and pins. Roller camshafts/followers are more commonly used to reduce camshaft lobe friction in modern engines.
Algae ( AL-jee, UK also AL-ghee; sing.: alga ) are any of a large and diverse group of photosynthetic organisms. It excludes the land plants (embryophytes). Such organisms range from microscopic unicellular microalgae (including cyanobacteria and phytoplankton) to seaweeds, multicellular macroalgae which may grow up to 50 metres (160 ft) in length. Most algae are aquatic (especially marine), and some form cohesive colonies. Freshwater algae include Charophyta such as the filamentous Spirogyra and the grasslike stoneworts. Most algae are plankton carried passively by water, although some macroalgae have holdfasts for anchorage. Algae are polyphyletic as they have multiple evolutionary origins. Although algae with two-membraned chloroplasts seem to form a paraphyletic group within the clade Archaeplastida, other algae with chloroplasts that have three or more membranes evolved from protists that acquired photosynthesis after engulfing archaeplastids. Chlorophytes, rhodophytes (red algae) and glaucophytes (grey algae) have primary chloroplasts directly derived from endosymbiont cyanobacteria, while diatoms, cryptomonads, euglenoids and phaeophyceae (brown algae) have secondary chloroplasts derived from indirectly endosymbiont red algae or green algae. Most algae are single-celled organisms without roots, leaves, or stems. Most are photoautotrophs and the main primary producers of aquatic ecosystems, although some are mixotrophs that derive metabolic energy both from internal photosynthesis and from foraging external nutrients.
Sources: en.wikipedia.org
In T cells, IRAP regulates the trafficking of TCD3ζ chains, that are recruited to IRAP intracellular vesicles, as well as endosomal signalling by the TCR complex. IRAP depletion increases the TCR levels at the cell surface which, however, display defective signalling. Other studies demonstrated that IRAP regulates Toll-like receptor 9 (TLR9) activation by delaying maturation of TLR9-containing endosomes to lysosomes and limiting, as a consequence, TLR9 cleavage and activation. Finally, IRAP has an important role in the secretion of the proinflammatory cytokines TNFa and IL-6 by mast cells. In the absence of IRAP, the trafficking of vesicles containing TNFα and IL-6 from the Golgi to the plasma membrane is impaired.
The catalytic cycle begins with coordination of the Cu(I) species to the olefin, followed by oxidative addition at the γ position and an allylic shift to displace the leaving group. This generates a Cu(III) allyl complex intermediate. Finally, reductive elimination yields the final product and regenerates Cu(I). A Cu(III) intermediate has not been confirmed by isolation from allylic substitutions, but Cu(III) intermediates have been isolated before, thus providing credence to the proposed mechanism. If reductive elimination does not occur fast enough, the γ allyl complex can isomerize to the α allyl complex and yield the α substituted isomer as a byproduct. This side pathway can be prevented by using electron withdrawing ligands on copper, typically a cyanide or halide ligand, which promote reductive elimination.
==== On-farm efficiency ==== On-farm, precision agriculture technologies can minimize inputs required for a given yield. For example, variable-rate application (VRA) technologies can apply precise amounts of water, fertilizer, pesticide, herbicide, etc. A number of empirical studies find that VRA improves input use efficiency. Using VRA alongside geo-spatial mapping, farmers can apply inputs to hyper-localized regions of their farm, sometimes down to the individual plant level. Reducing input use lowers costs and lessens negative environmental impacts. Furthermore, empirical evidence indicates precision agriculture technologies can increase yields. On U.S. peanut farms, guidance systems are associated with a 9% increase in yield, and soil maps are associated with a 13% increase in yield. One study in Argentina found that a precision agriculture approach based on crop physiological principles could result in 54% higher farm output. Digital agriculture can improve the allocative efficiency of physical capital within and between farms. Often touted as "Uber for tractors," equipment-sharing platforms like Hello Tractor, WeFarmUp, MachineryLink Solutions, TroTro Tractor, and Tringo facilitate farmer rental of expensive machinery, an on-demand model with parallels to Public transport. These platforms are an example of agricultural Fleet management, often coordinated with Fleet management software. By facilitating a market for equipment sharing, telematics technology ensures fewer tractors sit idle and allows owners to make extra income.
Notch signaling is triggered via direct cell-to-cell contact, mediated by interactions between the Notch receptor protein in the signal receiving cell and a ligand in an adjacent signal transmitting cell. These type 1 single-pass transmembrane proteins fall into the Delta/Serrate/Lag-2 (DSL) family of proteins which is named after the three canonical Notch ligands. Delta and Serrate are found in Drosophila while Lag-2 is found in C. elegans. Humans contain 3 Delta homologs, Delta-like 1, 3, and 4, as well as two Serrate homologs, Jagged 1 and 2. Notch proteins consist of a relatively short intracellular domain and a large extracellular domain with one or more EGF motifs and a N-terminal DSL-binding motif. EGF repeats 11-12 on the Notch extracellular domain have been shown to be necessary and sufficient for trans signaling interactions between Notch and its ligands. Additionally, EGF repeats 24-29 have been implicated in inhibition of cis interactions between Notch and ligands co-expressed in the same cell.
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes, from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis. In the latter case, an injection may produce a small dent at the injection site. Lipoatrophy occurs in HIV-associated lipodystrophy, one cause of which is an adverse drug reaction that is associated with some antiretroviral medications. A more general term for an abnormal or degenerative condition of the entire body's adipose tissue is lipodystrophy.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.